Previous portfolio companies

Syncona takes a long-term approach to founding and building companies to take products to market and is focused on delivering risk-adjusted returns for our shareholders

Our strategic capital pool underpins our long-term approach and enables us to fund our companies to succeed. This pool of capital also ensures we have full control and flexibility over the management of our portfolio and we seek never to be a forced seller. From time to time we may choose to divest an asset if there is an opportunity to capture an attractive risk adjusted return for our shareholders and it is the right outcome for the portfolio company. To date, we have divested two Syncona founded portfolio companies.

2019

Nightstar was acquired by Biogen for $877 million in June 2019, and delivered a 4.5x return on Syncona's original investment of £56.4 million.
Syncona announced the sale of Blue Earth Diagnostics to Bracco Imaging for $476 million in June 2019, and delivered a 10x return on Syncona's original investment of £35.3 million.